7,13-Dioxa-10,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7,13-Dioxa-10,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene
• 英文别名: 7,13-dioxa-10,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene
• 化学式: C₁₆H₁₆N₄O₂
• 分子量: 296.32
• InChiKey: LWYTXLXKETYIAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] MACROCYCLIC SALT-INDUCIBLE KINASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA KINASE INDUCTIBLE PAR UN SEL
  申请人：ONCODESIGN SA

  公开号：WO2014140313A1

  公开（公告）日：2014-09-18

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

  本发明涉及大环化合物以及含有作为激酶抑制剂，特别是SIK激酶抑制剂，尤其是SIK1、SIK2和/或SIK3以及/或其突变体的所述化合物的组合物，用于诊断、预防及/或治疗与SIK激酶相关的疾病。此外，本发明还提供了使用所述化合物的方法，例如作为药物或诊断剂。
• MACROCYCLIC SALT-INDUCIBLE KINASE INHIBITORS
  申请人：ONCODESIGN S.A.

  公开号：US20160024113A1

  公开（公告）日：2016-01-28

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
• US9586975B2
  申请人：——

  公开号：US9586975B2

  公开（公告）日：2017-03-07